NovoCure Limited (NVCR) exhibits 74.5% gross margins and -27.5% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 74.5% gross profitability converts into -23.5% operating margin and -27.5% ROIC, outpacing sector cost of capital.
ROIC: -27.5% // GM: 74.5%YoY revenue trajectory of +8.3% paired with -4.96% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.3% // FCF YLD: -4.96%Altman Z-Score of 0.54 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.54 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $13.11 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend -20.8% net margins.
NET MARGIN: -20.8% // D/E: 0.57x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NVCR & activate live FRED threshold breach alerts.